ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO497

Genetic Determinants of Ultrafiltration With Peritoneal Dialysis

Session Information

Category: Dialysis

  • 702 Dialysis: Home Dialysis and Peritoneal Dialysis


  • Stanaway, Ian Byrell, University of Washington School of Medicine, Seattle, Washington, United States
  • Devuyst, Olivier, University of Zurich, Zurich, Switzerland
  • Perl, Jeffrey, University of Toronto, Toronto, Ontario, Canada
  • Lambie, Mark, Keele University, Keele, Staffordshire, United Kingdom
  • Morelle, Johann, Cliniques Universitaires Saint-Luc, Brussels, Belgium
  • Jarvik, Gail P., University of Washington School of Medicine, Seattle, Washington, United States
  • Jain, Arsh, London Health Sciences Center, London, Ontario, Canada
  • Himmelfarb, Jonathan, University of Washington School of Medicine, Seattle, Washington, United States
  • Heimburger, Olof, Karolinska Universitetssjukhuset, Stockholm, Sweden
  • Johnson, David W., Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
  • Pirkle, James L., Wake Forest University, Winston-Salem, North Carolina, United States
  • Robinson, Bruce M., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Stenvinkel, Peter, Karolinska Universitetssjukhuset, Stockholm, Sweden
  • Davies, Simon J., Keele University, Keele, Staffordshire, United Kingdom
  • Mehrotra, Rajnish, University of Washington School of Medicine, Seattle, Washington, United States

Group or Team Name

  • Bio-PD Consortium

The inter-individual variability in the peritoneal dialysis (PD) ultrafiltration (UF) capacity is largely unexplained by demographic and clinical variables. We tested the hypothesis that common genetic variants are associated with variability in UF.


The Bio-PD study enrolled participants from 69 centers in 6 countries. The phenotype of UF volume at 4 hours was obtained from the 1st peritoneal equilibration test (PET) when starting PD. Genotyping was done with the Illumina InfiniumOmni2-5 array and imputed using the Michigan Imputation Server. Heritability was estimated using genomic-restricted maximum likelihood analysis, genome-wide association was performed for single nucleotide variants (SNVs) with minor allele frequency >2%, and gene-wise analyses were done with the Generalized Berk-Jones test. Analyses were adjusted for sex, age, body mass index, country, diabetes, dialysate dextrose concentration, interval between PD start and PET, and principal components of ancestry. Additional analyses included 4-h Dialysate/Plasma (D/P) creatinine ratio as covariate.


Analysis included 2413 participants (64% men, 32% diabetes, 82% White). The PETs were done at a median of 63 days (IQR 36-121) from PD start, 78% were completed with 2.5% dextrose, with a mean 4-h D/P creatinine of 0.70 and a median UF of 250mL (IQR 0-494). The heritability of UF was estimated at 58% and 42% in models without and with 4-h D/P creatinine, respectively (p=6x10-4 and 0.01). No SNV reached genome-wide significance using 7,052,235 SNVs. Analyses testing association with 18,330 genes showed significant association of 3 genes at a false discovery rate (FDR) <10% (PTGES FDR=0.02, GPHN FDR=0.04, SLC24A3 FDR=0.05). Further adjustment for 4-h D/P creatinine showed association with 2 genes remained significant (PTGES and SLC24A3).


Common genetic variants account for a substantial proportion of the variability in UF and these analyses suggest a potential association with variation in PTGES and SLC24A3 genes.


  • NIDDK Support